Addressing market access obstacles for rare bleeding disorders
In the latest edition of Deep Dive: Market Access II, Stefan Bosbach from phamax scrutinises the situation for people with rare bleeding disorders, including the challenges in recording the overall burden of the disease and the severity of the condition, which are hampering access to the right treatments.
Points covered in his article include:
- Congenital Factor XIII is considered the rarest bleeding disorder but has the highest incidence of intracranial haemorrhage, so correct diagnosis is important.
- The barriers to market access are more prevalent in emerging economies, with lower use of replacement factors to manage bleeding disorders.
- Research is moving towards more effective and less frequent interventions, such as monoclonal antibodies and gene therapy.
Read the full article here.
Please note that Deep Dive is best viewed in full-screen mode.
Read the latest full edition of Deep Dive: Market Access II here.
If you would like to read previous editions of Deep Dive and sign up to receive future editions, please visit the Deep Dive page on the website.